Vogt-Kayanagi-Harada-Like Uveitis Induced by Dabrafenib/Trametinib Therapy for Cutaneous Malignant Melanoma

• Published in: Ophthalmic surgery, lasers & imaging Vol. 54; no. 8; pp. 477 - 480
• Main Authors: Kaymak, Nilufer Zorlutuna, Kaplan, Aysin Tuba
• Format: Journal Article
• Language: English
• Published: United States Slack, Inc 01.08.2023; SLACK INCORPORATED
• Subjects: Antimitotic agents; Antineoplastic agents; Cancer; Cancer therapies; Care and treatment; Case reports; Chemotherapy; Complications and side effects; Conjunctivitis; Corticosteroids; Development and progression; Drug dosages; Edema; Female; Humans; Immunotherapy; Inflammation; Kinases; Medical imaging; Medical prognosis; Melanoma; Melanoma - drug therapy; Melanoma, Cutaneous Malignant; Metastasis; Middle Aged; Optics; Patients; Prognosis; Skin cancer; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; Steroids; Therapy; Tomography; Uveitis; Uveitis - chemically induced; Uveitis - diagnosis; Uveitis - drug therapy; British Columbia Canada; Canada
• ISSN: 2325-8160; 2325-8179
• DOI: 10.3928/23258160-20230524-01

A 54-year-old woman with cutaneous malignant melanoma developed Vogt-Kayanagi-Harada (VKH)-like uveitis induced by dabrafenib/trametinib therapy. Dabrafenib was discontinued but she continued to use trametinib due to the risk of disease progression. Intraocular inflammation resolved after cessation of dabrafenib and administration of topical and systemic corticosteroids. Our patient outlines the importance of recognizing VKH-like uveitis as a consequence of dabrafenib/trametinib therapy in melanoma patients and highlights a question about the potential role of each drug in developing uveitis. .